2024
Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC
McQuaid C, Ryckman T, Menzies N, White R, Cohen T, Kendall E. Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: 1571-1579. PMID: 39043388, PMCID: PMC11286077, DOI: 10.3201/eid3008.240541.Peer-Reviewed Original ResearchConceptsResistance to novel drugsStandard of careAntimicrobial resistanceIncreasing prevalence of antimicrobial resistancePrevalence of antimicrobial resistanceIncreased prevalenceDrug susceptibility testingCompare treatment outcomesFirst-line drugsNovel drugsTB patient cohortTreatment regimensPatient cohortNew tuberculosisRegimensTreatment outcomesComponent drugsDrugCohortTuberculosisCDCUniversal useClinicCarePrevalence
2023
Transmission modeling to infer tuberculosis incidence prevalence and mortality in settings with generalized HIV epidemics
Dodd P, Shaweno D, Ku C, Glaziou P, Pretorius C, Hayes R, MacPherson P, Cohen T, Ayles H. Transmission modeling to infer tuberculosis incidence prevalence and mortality in settings with generalized HIV epidemics. Nature Communications 2023, 14: 1639. PMID: 36964130, PMCID: PMC10037365, DOI: 10.1038/s41467-023-37314-1.Peer-Reviewed Original ResearchConceptsHigh HIV prevalence settingsEstimation of burdenHIV prevalence settingsGeneralized HIV epidemicsTB transmission modelAntiretroviral therapyTB infectionTB incidenceHIV prevalenceTB prevalencePrevalence settingsTB epidemicHIV epidemicHigh burdenBurden estimatesNotification dataAnnual riskSingle pathogenIntervention impactTherapy effectsTuberculosisPrevalenceEpidemicBurdenAfrican countries
2022
National survey in South Africa reveals high tuberculosis prevalence among previously treated people
Marx FM, Hesseling AC, Martinson N, Theron G, Cohen T. National survey in South Africa reveals high tuberculosis prevalence among previously treated people. The Lancet Infectious Diseases 2022, 22: 1273. PMID: 36029778, DOI: 10.1016/s1473-3099(22)00494-7.Peer-Reviewed Original ResearchNeighbourhood prevalence-to-notification ratios for adult bacteriologically-confirmed tuberculosis reveals hotspots of underdiagnosis in Blantyre, Malawi
Khundi M, Carpenter JR, Corbett EL, Feasey HRA, Soko RN, Nliwasa M, Twabi H, Chiume L, Burke RM, Horton KC, Dodd PJ, Cohen T, MacPherson P. Neighbourhood prevalence-to-notification ratios for adult bacteriologically-confirmed tuberculosis reveals hotspots of underdiagnosis in Blantyre, Malawi. PLOS ONE 2022, 17: e0268749. PMID: 35605004, PMCID: PMC9126376, DOI: 10.1371/journal.pone.0268749.Peer-Reviewed Original ResearchConceptsCase notification ratesPrevalence surveyNotification ratioNeighbourhood prevalenceTB case notification ratesXpert MTB/RIFCase-finding interventionsTrue disease burdenChest X-ray screeningTB prevalence surveyTB surveillance systemMTB/RIFDiagnosis of tuberculosisSputum smear microscopyTB clinicTB patientsRespiratory infectionsTB prevalenceDisease burdenNotification ratesSmear microscopyX-ray screeningTuberculosisPrevalenceUrban tuberculosisEvaluating spatially adaptive guidelines for the treatment of gonorrhea to reduce the incidence of gonococcal infection and increase the effective lifespan of antibiotics
Yaesoubi R, Cohen T, Hsu K, Gift TL, St. Cyr SB, Salomon JA, Grad YH. Evaluating spatially adaptive guidelines for the treatment of gonorrhea to reduce the incidence of gonococcal infection and increase the effective lifespan of antibiotics. PLOS Computational Biology 2022, 18: e1009842. PMID: 35139073, PMCID: PMC8863219, DOI: 10.1371/journal.pcbi.1009842.Peer-Reviewed Original ResearchConceptsIncidence of gonorrhoeaTreatment guidelinesResistance prevalenceGonorrhea casesTreatment of gonorrheaNational surveillance systemPrevalence of resistanceTransmission dynamic modelGonococcal infectionGonorrhea treatmentMSM populationAntibiotic susceptibilityGonorrheaStandardized guidelinesSurveillance dataPrevalenceIncidenceAntibioticsPotential strategySurveillance systemAbsence of pointsGuidelinesCurrent strategiesEffective lifespanMenSpatially targeted digital chest radiography to reduce tuberculosis in high-burden settings: A study of adaptive decision making
de Villiers AK, Dye C, Yaesoubi R, Cohen T, Marx FM. Spatially targeted digital chest radiography to reduce tuberculosis in high-burden settings: A study of adaptive decision making. Epidemics 2022, 38: 100540. PMID: 35093849, PMCID: PMC8983993, DOI: 10.1016/j.epidem.2022.100540.Peer-Reviewed Original ResearchConceptsHigh-burden settingsTB casesTB prevalenceChest radiographyAdditional TB casesCase-finding yieldTB prevalence estimatesHigh-burden populationsCommunity-randomized trialNumber of screeningsTB controlXpert UltraScreening roundNotification ratesPrevalence estimatesTuberculosisPrevalenceDigital chest radiographyScreeningTrialsInterventionRadiography
2017
Polyclonal Pulmonary Tuberculosis Infections and Risk for Multidrug Resistance, Lima, Peru - Volume 23, Number 11—November 2017 - Emerging Infectious Diseases journal - CDC
Nathavitharana RR, Shi CX, Chindelevitch L, Calderon R, Zhang Z, Galea JT, Contreras C, Yataco R, Lecca L, Becerra MC, Murray MB, Cohen T. Polyclonal Pulmonary Tuberculosis Infections and Risk for Multidrug Resistance, Lima, Peru - Volume 23, Number 11—November 2017 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2017, 23: 1887-1890. PMID: 29048297, PMCID: PMC5652442, DOI: 10.3201/eid2311.170077.Peer-Reviewed Original ResearchConceptsTreatment of tuberculosisHost Mycobacterium tuberculosis diversityMultidrug-resistant TBInfectious Diseases journal - CDCPulmonary TB patientsPulmonary tuberculosis infectionTB patientsTuberculosis infectionPolyclonal infectionsSimple infectionMultidrug resistanceInfectionPatientsTuberculosisPrevalenceDiagnosisAntimicrobial Resistance Risks of Cholera Prophylaxis for United Nations Peacekeepers
Kunkel A, Lewnard JA, Pitzer VE, Cohen T. Antimicrobial Resistance Risks of Cholera Prophylaxis for United Nations Peacekeepers. Antimicrobial Agents And Chemotherapy 2017, 61: 10.1128/aac.00026-17. PMID: 28533237, PMCID: PMC5527623, DOI: 10.1128/aac.00026-17.Peer-Reviewed Original ResearchConceptsDrug-resistant infectionsAntimicrobial chemoprophylaxisDrug-sensitive infectionsDrug resistance generationCholera importationChemoprophylaxisDrug resistanceImportation eventsInfectionAntibiotic resistanceAntimicrobial resistance risksRiskRelative benefitsResistance generationCholeraPotential resistance risksPotential benefitsResistance riskProphylaxisPrevalenceA Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis
Fofana MO, Shrestha S, Knight GM, Cohen T, White RG, Cobelens F, Dowdy DW. A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis. Antimicrobial Agents And Chemotherapy 2017, 61: 10.1128/aac.00498-16. PMID: 27956422, PMCID: PMC5328532, DOI: 10.1128/aac.00498-16.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsBayes TheoremBiological AvailabilityComputer SimulationDrug Administration ScheduleDrug Resistance, Multiple, BacterialExtensively Drug-Resistant TuberculosisFluoroquinolonesHumansMicrobial Sensitivity TestsModels, StatisticalMycobacterium tuberculosisPyrazinamideRifampinTuberculosis, PulmonaryConceptsCompanion drugsExtensively Drug-Resistant TuberculosisSecond-line treatmentFirst-line treatmentSecond-line regimensDrug-resistant tuberculosisUse of pyrazinamideExtensive drug resistanceDrug resistance dataEmergence of strainsEmergence of mutationsXDR-TBSequential regimensHIV infectionAlternative drugsResistance amplificationPyrazinamide resistanceProlonged treatmentCombination antimicrobialsDrug resistanceInfectious diseasesPrevalenceProportion of simulationsAppropriate useRegimens
2016
Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective
Kendall EA, Cohen T, Mitnick CD, Dowdy DW. Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. International Journal Of Infectious Diseases 2016, 56: 185-189. PMID: 28007660, PMCID: PMC5576040, DOI: 10.1016/j.ijid.2016.12.010.Peer-Reviewed Original ResearchConceptsSecond-line drug susceptibility testingRifampin-resistant tuberculosisDrug susceptibility testingSecond-line drug resistanceDrug resistanceSusceptibility testingHigh-burden settingsSecond-line drugsDrug-resistant tuberculosisEffective regimensTreatment failureTreatment outcomesSmall incremental costEpidemiologic benefitsResistance amplificationPatientsTuberculosisIncremental costMost settingsWidespread implementationSettingRegimensPrevalenceHigh burden of prevalent tuberculosis among previously treated people in Southern Africa suggests potential for targeted control interventions
Marx FM, Floyd S, Ayles H, Godfrey-Faussett P, Beyers N, Cohen T. High burden of prevalent tuberculosis among previously treated people in Southern Africa suggests potential for targeted control interventions. European Respiratory Journal 2016, 48: 1227-1230. PMID: 27390274, PMCID: PMC5512114, DOI: 10.1183/13993003.00716-2016.Peer-Reviewed Original ResearchConceptsHigh-burden settingsHigh TB prevalenceRecurrent tuberculosisExogenous reinfectionPrevalent tuberculosisTB prevalenceSuccessful treatmentHigh burdenImportant underlying mechanismHigh riskHigh incidenceControl interventionsTargeted interventionsTuberculosisUnderlying mechanismOne-thirdInterventionBurdenCape TownIndividualsReinfectionPrevalenceIncidenceDiseaseSettingUse of Lot Quality Assurance Sampling to Ascertain Levels of Drug Resistant Tuberculosis in Western Kenya
Jezmir J, Cohen T, Zignol M, Nyakan E, Hedt-Gauthier BL, Gardner A, Kamle L, Injera W, Carter EJ. Use of Lot Quality Assurance Sampling to Ascertain Levels of Drug Resistant Tuberculosis in Western Kenya. PLOS ONE 2016, 11: e0154142. PMID: 27167381, PMCID: PMC4864281, DOI: 10.1371/journal.pone.0154142.Peer-Reviewed Original ResearchConceptsMDR-TBDrug resistanceResistant tuberculosisLot Quality Assurance Sampling methodologyMulti-drug resistant tuberculosisPositive TB patientsDrug resistance surveillanceDrug-resistant tuberculosisTB drug resistanceRural settingsPoly-resistant strainsTB patientsWestern KenyaLot Quality AssuranceLow prevalencePatientsResistance surveillancePrevalenceTuberculosisLQASSettingLow levelsDifferent geographic settingsUrban settingsLevelsWithin-Host Heterogeneity of Mycobacterium tuberculosis Infection Is Associated With Poor Early Treatment Response: A Prospective Cohort Study
Cohen T, Chindelevitch L, Misra R, Kempner ME, Galea J, Moodley P, Wilson D. Within-Host Heterogeneity of Mycobacterium tuberculosis Infection Is Associated With Poor Early Treatment Response: A Prospective Cohort Study. The Journal Of Infectious Diseases 2016, 213: 1796-1799. PMID: 26768249, PMCID: PMC4857469, DOI: 10.1093/infdis/jiw014.Peer-Reviewed Original ResearchConceptsMonths of treatmentMycobacterium tuberculosis infectionTuberculosis infectionTreatment responsePoor early treatment responseProspective cohort studyInitiation of treatmentM. tuberculosis infectionRepetitive units-variable numberEarly treatment responsePersistent culture positivityCohort studyClinical managementCulture positivityHigher oddsInfectionTuberculosisPrevalenceTreatmentMonthsResponsePatientsKwaZulu-NatalHost heterogeneityPositivity
2015
How could preventive therapy affect the prevalence of drug resistance? Causes and consequences
Kunkel A, Colijn C, Lipsitch M, Cohen T. How could preventive therapy affect the prevalence of drug resistance? Causes and consequences. Philosophical Transactions Of The Royal Society B Biological Sciences 2015, 370: 20140306. PMID: 25918446, PMCID: PMC4424438, DOI: 10.1098/rstb.2014.0306.Peer-Reviewed Original ResearchConceptsPreventative therapyDrug resistanceDrug-sensitive pathogensProphylactic antimicrobial therapyLong-term prevalenceSmall pilot studyActive diseaseOverall prevalenceAntimicrobial therapyPrevalencePilot studyTherapyPopulation-level changesPotential population-level effectsDirect effectLevel of coveragePopulation-level effectsHIVTuberculosisMalariaDiseaseCareOrigin and Proliferation of Multiple-Drug Resistance in Bacterial Pathogens
Chang HH, Cohen T, Grad YH, Hanage WP, O'Brien TF, Lipsitch M. Origin and Proliferation of Multiple-Drug Resistance in Bacterial Pathogens. Microbiology And Molecular Biology Reviews 2015, 79: 101-116. PMID: 25652543, PMCID: PMC4402963, DOI: 10.1128/mmbr.00039-14.Peer-Reviewed Original ResearchConceptsMDR infectionsPublic health threatMultiple drug resistanceHigh prevalenceMore effective interventionsDifferent underlying mechanismsMultidrug resistanceEffective interventionsHealth threatUnderlying mechanismInfectionBacterial pathogensMDRCommon mechanismDifferent pathogensProliferationPathogensPrevalenceHypothetical mechanism
2014
Magnitude and sources of bias in the detection of mixed strain M. tuberculosis infection
Plazzotta G, Cohen T, Colijn C. Magnitude and sources of bias in the detection of mixed strain M. tuberculosis infection. Journal Of Theoretical Biology 2014, 368: 67-73. PMID: 25553967, PMCID: PMC7011203, DOI: 10.1016/j.jtbi.2014.12.009.Peer-Reviewed Original ResearchConceptsMixed infectionsM. tuberculosis infectionIncidence of TBOutcome of treatmentPopulation-level interventionsFraction of casesTuberculosis infectionMinority strainsActual prevalenceInfected individualsInfectionStudy designMycobacterium tuberculosisPrevalenceSputumTuberculosisDistinct strainsDifferent strainsSources of biasPrevious studiesPatientsSpecific reasonsIncidenceIndividualsHow can mathematical models advance tuberculosis control in high HIV prevalence settings?
Houben RM, Dowdy DW, Vassall A, Cohen T, Nicol MP, Granich RM, Shea JE, Eckhoff P, Dye C, Kimerling ME, White RG, . How can mathematical models advance tuberculosis control in high HIV prevalence settings? The International Journal Of Tuberculosis And Lung Disease 2014, 18: 509-514. PMID: 24903784, PMCID: PMC4436821, DOI: 10.5588/ijtld.13.0773.Peer-Reviewed Original ResearchConceptsHigh HIV prevalence settingsHIV prevalence settingsTB-HIVTuberculosis controlPrevalence settingsHigh human immunodeficiency virus (HIV) prevalenceHuman immunodeficiency virus (HIV) prevalenceTB ModellingHealth policy makersDifficult diagnosisDisease progressionHigh riskHigh mortalityHealth systemNatural progressionVirus prevalencePublic healthProgressionMortalityPrevalenceSettingAnalysis ConsortiumDiagnosisExpert discussion
2011
Diabetes mellitus and tuberculosis in countries with high tuberculosis burdens: individual risks and social determinants
Goldhaber-Fiebert JD, Jeon CY, Cohen T, Murray MB. Diabetes mellitus and tuberculosis in countries with high tuberculosis burdens: individual risks and social determinants. International Journal Of Epidemiology 2011, 40: 417-428. PMID: 21252210, PMCID: PMC3621385, DOI: 10.1093/ije/dyq238.Peer-Reviewed Original ResearchConceptsDiabetes prevalenceTB prevalenceSocial determinantsHigh TB burdenBody mass indexHigh tuberculosis burdenType 2 diabetesIndividual-level risk factorsWorld Health SurveyTB burdenDiabetes mellitusPrevalent tuberculosisTuberculosis burdenMass indexIndividual-level riskBody of evidenceRisk factorsHealth SurveyDiabetesTuberculosisPrevalenceLow-income countriesHealth policyIndividual riskPopulation health
2009
What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae?
Colijn C, Cohen T, Fraser C, Hanage W, Goldstein E, Givon-Lavi N, Dagan R, Lipsitch M. What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae? Journal Of The Royal Society Interface 2009, 7: 905-919. PMID: 19940002, PMCID: PMC2871802, DOI: 10.1098/rsif.2009.0400.Peer-Reviewed Original ResearchConceptsDrug-resistant strainsStreptococcus pneumoniaeInfectious diseasesDrug-susceptible strainsHigher reproduction numberCent prevalenceSubstantial prevalencePersistent coexistenceDrug resistanceMultiple infectionsAntimicrobial useResistant strainsBacterial spreadAntimicrobial resistancePrevalenceDiseasePneumoniaeOutcomesReproduction numberTreatmentHost interactionsPathogensCoinfectionMathematical models of the epidemiology and control of drug-resistant TB
Cohen T, Dye C, Colijn C, Williams B, Murray M. Mathematical models of the epidemiology and control of drug-resistant TB. Expert Review Of Respiratory Medicine 2009, 3: 67-79. PMID: 20477283, DOI: 10.1586/17476348.3.1.67.Peer-Reviewed Original ResearchDrug-resistant TBDrug resistanceMultiple drug-resistant Mycobacterium tuberculosisDrug-resistant Mycobacterium tuberculosisDrug-resistant M. tuberculosisCombination chemotherapyTB controlM. tuberculosisMycobacterium tuberculosisAntibiotic resistanceRecent reportsTuberculosisEpidemiologyTBExtrinsic determinantsInterventionCost effectivenessReproductive capacityChemotherapyControlPrevalence